Hypha Labs (Hypha Labs) Forward PE Ratio : 0.00 (As of May. 15, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Hypha Labs Forward PE Ratio?

Hypha Labs's Forward PE Ratio for today is 0.00.

Hypha Labs's PE Ratio without NRI for today is 0.00.

Hypha Labs's PE Ratio for today is 7.68.

Hypha Labs Forward PE Ratio Historical Data

The historical data trend for Hypha Labs's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypha Labs Forward PE Ratio Chart

Hypha Labs Annual Data

Trend

Forward PE Ratio

Hypha Labs Quarterly Data

Forward PE Ratio

Competitive Comparison of Hypha Labs's Forward PE Ratio

For the Diagnostics & Research subindustry, Hypha Labs's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hypha Labs's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Hypha Labs's Forward PE Ratio falls into.

Hypha Labs Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Hypha Labs (OTCPK:DIGP) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Hypha Labs Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Hypha Labs's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Hypha Labs (Hypha Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hypha Labs Inc (OTCPK:DIGP) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118

Website

https://www.digipath.com

DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.

Executives

A Stone Douglass	director	10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank	director	19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda	officer: Chief Executive Officer	111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann	director	1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben	director	430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser	director	4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer	director	287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco	director	611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson	officer: Chief Financial Officer	3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner	director	28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc	10 percent owner	16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin	director, officer: President	C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee	10 percent owner	3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen	director, 10 percent owner, officer: CFO	8908 SPLITARROW DRIVE, AUSTIN TX 78717